Yahong Pharmaceuticals: Non-invasive treatment product for precancerous cervical lesions, XiweiTa®, approved

2026-03-04 09:40:50

Abstract generation in progress

Recently, YAHONG Pharmaceutical announced that its core product APL-1702 (brand name: Xivetha®/CEVIRA®, generic name: Hydroxyaminohexanoic Acid Hydrochloride Ointment Cervical Photodynamic Therapy System) has received the Drug Registration Certificate issued by the National Medical Products Administration of China, officially approved for market launch.

This product is a non-surgical, non-invasive treatment for patients with Cervical Intraepithelial Neoplasia grade 2 (CIN2), filling a clinical gap in this treatment area and redefining the blue ocean market for non-invasive therapies in this field.

(YAHONG Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes